A novel calcium-dependent kinase inhibitor, bumped kinase inhibitor 1517, cures cryptosporidiosis in immunosuppressed mice

Alejandro Castellanos, Hayley Sparks, Samantha Nava, Wenlin Huang, Zhongsheng Zhang, Kasey Rivas, Matthew A. Hulverson, Lynn K. Barrett, Kayode K. Ojo, Erkang Fan, Wesley C. Van Voorhis, A. Clinton White

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Cryptosporidium is recognized as one of the main causes of childhood diarrhea worldwide. However, the current treatment for cryptosporidiosis is suboptimal. Calcium flux is essential for entry in apicomplexan parasites. Calcium-dependent protein kinases (CDPKs) are distinct from protein kinases of mammals, and the CDPK1 of the apicomplexan Cryptosporidium lack side chains that typically block a hydrophobic pocket in protein kinases. We exploited this to develop bumped kinase inhibitors (BKIs) that selectively target CDPK1. We have shown that several BKIs of Cryptosporidium CDPK1 potently reduce enzymatic activity and decrease parasite numbers when tested in vitro. In the present work, we studied the anticryptosporidial activity of BKI-1517, a novel BKI. The half maximal effective concentration for Cryptosporidium parvum in HCT-8 cells was determined to be approximately 50 nM. Silencing experiments of CDPK1 suggest that BKI-1517 acts on CDPK1 as its primary target. In a mouse model of chronic infection, 5 of 6 SCID/beige mice (83.3%) were cured after treatment with a single daily dose of 120 mg/kg BKI-1517. No side effects were observed. These data support advancing BKI-1517 as a lead compound for drug development for cryptosporidiosis.

Original languageEnglish (US)
Pages (from-to)1850-1855
Number of pages6
JournalJournal of Infectious Diseases
Volume214
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Cryptosporidiosis
Phosphotransferases
Calcium
Cryptosporidium
Protein Kinases
Parasites
Cryptosporidium parvum
SCID Mice
Mammals
Diarrhea
Infection
Pharmaceutical Preparations

Keywords

  • BKI
  • CDPK
  • CDPK1
  • Cryptosporidiosis
  • Cryptosporidium
  • Kinase inhibitors
  • SiRNA

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

A novel calcium-dependent kinase inhibitor, bumped kinase inhibitor 1517, cures cryptosporidiosis in immunosuppressed mice. / Castellanos, Alejandro; Sparks, Hayley; Nava, Samantha; Huang, Wenlin; Zhang, Zhongsheng; Rivas, Kasey; Hulverson, Matthew A.; Barrett, Lynn K.; Ojo, Kayode K.; Fan, Erkang; Van Voorhis, Wesley C.; White, A. Clinton.

In: Journal of Infectious Diseases, Vol. 214, No. 12, 01.12.2016, p. 1850-1855.

Research output: Contribution to journalArticle

Castellanos, A, Sparks, H, Nava, S, Huang, W, Zhang, Z, Rivas, K, Hulverson, MA, Barrett, LK, Ojo, KK, Fan, E, Van Voorhis, WC & White, AC 2016, 'A novel calcium-dependent kinase inhibitor, bumped kinase inhibitor 1517, cures cryptosporidiosis in immunosuppressed mice', Journal of Infectious Diseases, vol. 214, no. 12, pp. 1850-1855. https://doi.org/10.1093/infdis/jiw481
Castellanos, Alejandro ; Sparks, Hayley ; Nava, Samantha ; Huang, Wenlin ; Zhang, Zhongsheng ; Rivas, Kasey ; Hulverson, Matthew A. ; Barrett, Lynn K. ; Ojo, Kayode K. ; Fan, Erkang ; Van Voorhis, Wesley C. ; White, A. Clinton. / A novel calcium-dependent kinase inhibitor, bumped kinase inhibitor 1517, cures cryptosporidiosis in immunosuppressed mice. In: Journal of Infectious Diseases. 2016 ; Vol. 214, No. 12. pp. 1850-1855.
@article{b81237ab0b1c42859dffbf21c5118de3,
title = "A novel calcium-dependent kinase inhibitor, bumped kinase inhibitor 1517, cures cryptosporidiosis in immunosuppressed mice",
abstract = "Cryptosporidium is recognized as one of the main causes of childhood diarrhea worldwide. However, the current treatment for cryptosporidiosis is suboptimal. Calcium flux is essential for entry in apicomplexan parasites. Calcium-dependent protein kinases (CDPKs) are distinct from protein kinases of mammals, and the CDPK1 of the apicomplexan Cryptosporidium lack side chains that typically block a hydrophobic pocket in protein kinases. We exploited this to develop bumped kinase inhibitors (BKIs) that selectively target CDPK1. We have shown that several BKIs of Cryptosporidium CDPK1 potently reduce enzymatic activity and decrease parasite numbers when tested in vitro. In the present work, we studied the anticryptosporidial activity of BKI-1517, a novel BKI. The half maximal effective concentration for Cryptosporidium parvum in HCT-8 cells was determined to be approximately 50 nM. Silencing experiments of CDPK1 suggest that BKI-1517 acts on CDPK1 as its primary target. In a mouse model of chronic infection, 5 of 6 SCID/beige mice (83.3{\%}) were cured after treatment with a single daily dose of 120 mg/kg BKI-1517. No side effects were observed. These data support advancing BKI-1517 as a lead compound for drug development for cryptosporidiosis.",
keywords = "BKI, CDPK, CDPK1, Cryptosporidiosis, Cryptosporidium, Kinase inhibitors, SiRNA",
author = "Alejandro Castellanos and Hayley Sparks and Samantha Nava and Wenlin Huang and Zhongsheng Zhang and Kasey Rivas and Hulverson, {Matthew A.} and Barrett, {Lynn K.} and Ojo, {Kayode K.} and Erkang Fan and {Van Voorhis}, {Wesley C.} and White, {A. Clinton}",
year = "2016",
month = "12",
day = "1",
doi = "10.1093/infdis/jiw481",
language = "English (US)",
volume = "214",
pages = "1850--1855",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - A novel calcium-dependent kinase inhibitor, bumped kinase inhibitor 1517, cures cryptosporidiosis in immunosuppressed mice

AU - Castellanos, Alejandro

AU - Sparks, Hayley

AU - Nava, Samantha

AU - Huang, Wenlin

AU - Zhang, Zhongsheng

AU - Rivas, Kasey

AU - Hulverson, Matthew A.

AU - Barrett, Lynn K.

AU - Ojo, Kayode K.

AU - Fan, Erkang

AU - Van Voorhis, Wesley C.

AU - White, A. Clinton

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Cryptosporidium is recognized as one of the main causes of childhood diarrhea worldwide. However, the current treatment for cryptosporidiosis is suboptimal. Calcium flux is essential for entry in apicomplexan parasites. Calcium-dependent protein kinases (CDPKs) are distinct from protein kinases of mammals, and the CDPK1 of the apicomplexan Cryptosporidium lack side chains that typically block a hydrophobic pocket in protein kinases. We exploited this to develop bumped kinase inhibitors (BKIs) that selectively target CDPK1. We have shown that several BKIs of Cryptosporidium CDPK1 potently reduce enzymatic activity and decrease parasite numbers when tested in vitro. In the present work, we studied the anticryptosporidial activity of BKI-1517, a novel BKI. The half maximal effective concentration for Cryptosporidium parvum in HCT-8 cells was determined to be approximately 50 nM. Silencing experiments of CDPK1 suggest that BKI-1517 acts on CDPK1 as its primary target. In a mouse model of chronic infection, 5 of 6 SCID/beige mice (83.3%) were cured after treatment with a single daily dose of 120 mg/kg BKI-1517. No side effects were observed. These data support advancing BKI-1517 as a lead compound for drug development for cryptosporidiosis.

AB - Cryptosporidium is recognized as one of the main causes of childhood diarrhea worldwide. However, the current treatment for cryptosporidiosis is suboptimal. Calcium flux is essential for entry in apicomplexan parasites. Calcium-dependent protein kinases (CDPKs) are distinct from protein kinases of mammals, and the CDPK1 of the apicomplexan Cryptosporidium lack side chains that typically block a hydrophobic pocket in protein kinases. We exploited this to develop bumped kinase inhibitors (BKIs) that selectively target CDPK1. We have shown that several BKIs of Cryptosporidium CDPK1 potently reduce enzymatic activity and decrease parasite numbers when tested in vitro. In the present work, we studied the anticryptosporidial activity of BKI-1517, a novel BKI. The half maximal effective concentration for Cryptosporidium parvum in HCT-8 cells was determined to be approximately 50 nM. Silencing experiments of CDPK1 suggest that BKI-1517 acts on CDPK1 as its primary target. In a mouse model of chronic infection, 5 of 6 SCID/beige mice (83.3%) were cured after treatment with a single daily dose of 120 mg/kg BKI-1517. No side effects were observed. These data support advancing BKI-1517 as a lead compound for drug development for cryptosporidiosis.

KW - BKI

KW - CDPK

KW - CDPK1

KW - Cryptosporidiosis

KW - Cryptosporidium

KW - Kinase inhibitors

KW - SiRNA

UR - http://www.scopus.com/inward/record.url?scp=85016075875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016075875&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiw481

DO - 10.1093/infdis/jiw481

M3 - Article

C2 - 27738055

AN - SCOPUS:85016075875

VL - 214

SP - 1850

EP - 1855

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 12

ER -